Cargando…
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients with estrogen receptor (ER)-positive malignancy will succumb to their disease. Herein we demonstrate that long-term estrogen deprivation (LTED) therapy among ER-positive brea...
Autores principales: | Liu, Shuying, Meng, Xiaolong, Chen, Huiqin, Liu, Wenbin, Miller, Todd, Murph, Mandi, Lu, Yiling, Zhang, Fan, Gagea, Mihai, Arteaga, Carlos L., Mills, Gordon B., Meric-Bernstam, Funda, González-Angulo, Ana M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253418/ https://www.ncbi.nlm.nih.gov/pubmed/24979294 |
Ejemplares similares
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023) -
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023) -
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
por: Fox, Emily M., et al.
Publicado: (2012) -
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
por: Meric-Bernstam, Funda, et al.
Publicado: (2012) -
Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)